EQRX — EQRx Share Price
Last trade - 00:00- $1.14bn
- -$71.09m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.97 | ||
| Price to Tang. Book | 0.97 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -33.71% | ||
| Return on Equity | -29.59% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2018 | 2019 | 2020 | 2021 | 2022 | 2023E | 2024E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | 1.3 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
EQRx, Inc. is a pharmaceutical company. The Company is engaged in developing medicines for some of the prevalent disease areas, including cancer and immune-inflammatory conditions. The Company brands include EQRx and Remaking Medicine. The Company's pipeline is comprised of approximately 10 programs, including both small molecules and biologics, with five clinical-stage programs, and several disclosed and undisclosed preclinical and drug engineering programs. Its clinical programs include Aumolertinib (EQ143), Lerociclib (EQ132), and Sugemalimab (EQ165). Aumolertinib (EQ143) is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI). Lerociclib (EQ132) is a novel and oral small molecule cyclin-dependent kinase (CDK) 4/6 inhibitor. Sugemalimab (EQ165, also known as CS1001) is an anti-programmed cell death-ligand 1 (PD-L1) monoclonal antibody.
Directors
- Last Annual
- December 31st, 2022
- Last Interim
- September 30th, 2023
- Incorporated
- January 25th, 2021
- Public Since
- January 1st, 1970
- No. of Shareholders
- 108
- No. of Employees
- 362
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Market
- Shares in Issue
- 487,696,181
- Address
- 50 Hampshire Street, CAMBRIDGE, 02139
- Web
- https://www.eqrx.com/
- Phone
- +1 6173152255
- Auditors
- Ernst & Young LLP
Upcoming Events for EQRX
Similar to EQRX
89bio
NASDAQ Global Market
Abivax SA
NASDAQ Global Market
AcelRx Pharmaceuticals
NASDAQ Global Market
AC Immune SA
NASDAQ Global Market
Acrivon Therapeutics
NASDAQ Global Market
FAQ
As of Today at 06:08 UTC, shares in EQRx are trading at $2.34. This share price information is delayed by 15 minutes.
Shares in EQRx last closed at $2.34 and the price had moved by -57.91% over the past 365 days. In terms of relative price strength the EQRx share price has underperformed the S&P500 Index by -61.94% over the past year.
The overall consensus recommendation for EQRx is Sell. You can view the full broker recommendation list by unlocking its StockReport.
EQRx does not currently pay a dividend.
EQRx does not currently pay a dividend.
EQRx does not currently pay a dividend.
To buy shares in EQRx you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $2.34, shares in EQRx had a market capitalisation of $1.14bn.
Here are the trading details for EQRx:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: EQRX
Based on an overall assessment of its quality, value and momentum EQRx is currently classified as a . The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in EQRx is $2.10. That is 10.26% below the last closing price of $2.34.
Analysts covering EQRx currently have a consensus Earnings Per Share (EPS) forecast of -$0.68 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like EQRx. Over the past six months, its share price has outperformed the S&P500 Index by +31.27%.
As of the last closing price of $2.34, shares in EQRx were trading +13.91% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The EQRx PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $2.34.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
We do not have data on EQRx's directors